High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$22K
$22,420
Total Sells (Filtered)
$180M
$180,966,381
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
KROS
P
Keros Therapeutics, Inc.
BIENAIME JEAN JACQUES
• Director
Discretionary BuyΔOwn +36.7%
2026-03-09
$22,420
|
||||||
| KROS |
Keros Therapeutics, Inc.
|
Director
Discretionary BuyΔOwn +36.7%
|
2026-03-09 | $22,420 | P | Form 4 |
| KROS |
Keros Therapeutics, Inc.
|
CEO
Sell to Cover
|
2026-02-19 | $113,433 | S | Form 4 |
|
KROS
S
Keros Therapeutics, Inc.
Cho Esther
• Officer • SVP, General Counsel
Sell to CoverΔOwn -10.7%
2026-02-18
$77,581
|
||||||
| KROS |
Keros Therapeutics, Inc.
|
Officer • SVP, General Counsel
Sell to CoverΔOwn -10.7%
|
2026-02-18 | $77,581 | S | Form 4 |
|
KROS
S
Keros Therapeutics, Inc.
Lerner Lorena Raquel
• Officer • Chief Science Officer
Sell to CoverΔOwn -11.1%
2026-02-18
$63,324
|
||||||
| KROS |
Keros Therapeutics, Inc.
|
Officer • Chief Science Officer
Sell to CoverΔOwn -11.1%
|
2026-02-18 | $63,324 | S | Form 4 |
| KROS |
Keros Therapeutics, Inc.
|
CFO
Sell to CoverΔOwn -10.8%
|
2026-02-18 | $77,483 | S | Form 4 |
|
KROS
S
Keros Therapeutics, Inc.
ADAR1 Capital Management, LLC
• 10% Owner
Discretionary Sell
2025-10-15
$95,659,436MEGAx3
|
||||||
| KROS |
Keros Therapeutics, Inc.
|
10% Owner
Discretionary Sell
|
2025-10-15 | $95,659,436MEGAx3 | S | Form 4 |
|
KROS
S
Keros Therapeutics, Inc.
Pontifax Management 4 G.P. (2015) Ltd.
• 10% Owner
Discretionary Sell
2025-10-15
$84,975,125MEGAx4
|
||||||
| KROS |
Keros Therapeutics, Inc.
|
10% Owner
Discretionary Sell
|
2025-10-15 | $84,975,125MEGAx4 | S | Form 4 |